These technologies could transform compounds like GHK-Cu, which are effective locally but limited by short systemic half-lives, into practical therapeutic tools
DIY methods, while cost-effective, lack these stringent controls and can vary in quality
Important Notes & Considerations While the potential benefits are compelling, here are a few caveats to keep in mind: The body of clinical research on DSIP is still relatively small, especially compared to many mainstream sleep therapies
Third-party HPLC-MS verified 99% purity
Additionally, due to inherent proclivity to hemolytic, thrombotic, and other medically threatening events, G6PD-deficient patients may be limited in treatment options available to them, particularly in the case of COVID-19 infection
This is the standard rationale offered for stacking the two compounds in preclinical work